Skip to main content
. 2024 Sep 25;17:17562864241281903. doi: 10.1177/17562864241281903

Figure 2.

Figure 2.

Forest plot comparing the risk of MACE in overweight or obese adults without diabetes treated with GLP-1 or GIP/GLP-1 RAs versus placebo.

GIP, glucose-dependent insulinotropic polypeptide; GLP-1 RA, glucagon-like peptide-1 receptor agonists; MACE, major adverse cardiovascular event.